Vanguard Portfolio Management
VIR icon

Vanguard Portfolio Management’s Vir Biotechnology VIR Stock Holding History

Vanguard Portfolio Management’s Portfolio VIR Stock Details VIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$117M Buy
11,495,215
+2,279,638
+25% +$21.7M 0.01% 1449
2026
Q1 		$82.6M Buy
+9,215,577
New +$73.4M ﹤0.01% 1509

Other funds holding VIR

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AVM
Arch Venture Management Chicago, Illinois $1.1B AUM 356.62% 1-Year Est. Return
SIAU
SB Investment Advisers (UK) London, United Kingdom $7.66B AUM 20.12% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
GP
GSK plc London $602M AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return

Vanguard Portfolio Management's VIR Position: Q2 2026 in Review

Vanguard Portfolio Management increased its Vir Biotechnology (VIR) stake by 25% in Q2 2026, buying an estimated $21.7M and bringing the position to 11,495,215 shares worth $117M. The position accounts for 0.01% of the portfolio, ranked #1449.

Vanguard Portfolio Management first reported a position in VIR in Q1 2026 and has held it in 2 quarters since. 236 funds tracked by Wall St. Rank hold VIR as of Q2 2026.

  • Vanguard Portfolio Management held 11,495,215 shares of Vir Biotechnology worth $117M as of Q2 2026.
  • Vanguard Portfolio Management bought 2,279,638 Vir Biotechnology shares in Q2 2026, an estimated $21.7M.
  • Vir Biotechnology made up 0.01% of Vanguard Portfolio Management's portfolio in Q2 2026, its #1449 holding.
  • Vanguard Portfolio Management first reported a position in Vir Biotechnology in Q1 2026 and has held it in 2 quarters since.
  • 236 funds tracked by Wall St. Rank held Vir Biotechnology as of Q2 2026.

Based on Vanguard Portfolio Management's 13F filing for Q2 2026, filed 13 Aug 2026.